Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 42.84 USD 2.37% Market Closed
Market Cap: 2.9B USD
Have any thoughts about
Merus NV?
Write Note

Merus NV
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Merus NV
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Merus NV
NASDAQ:MRUS
Total Equity
$703.3m
CAGR 3-Years
51%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Total Equity
$225.8m
CAGR 3-Years
11%
CAGR 5-Years
20%
CAGR 10-Years
30%
ProQR Therapeutics NV
NASDAQ:PRQR
Total Equity
€25m
CAGR 3-Years
-42%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Total Equity
$55.8m
CAGR 3-Years
-54%
CAGR 5-Years
-31%
CAGR 10-Years
-1%
argenx SE
XBRU:ARGX
Total Equity
$4.3B
CAGR 3-Years
13%
CAGR 5-Years
45%
CAGR 10-Years
71%
LAVA Therapeutics NV
NASDAQ:LVTX
Total Equity
$51.2m
CAGR 3-Years
89%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Merus NV
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

Merus NV, a Dutch biotechnology company, stands at the forefront of innovative cancer therapies, channeling its efforts into research and development of multispecific antibodies. Its proprietary technology platform, Biclonics®, ingeniously harnesses the power of full-length human antibodies to target multiple pathways in the treatment of cancer. Each Biclonics® candidate is designed to bind simultaneously to more than one target, acting like a precision-guided missile that seeks out cancer cells and disrupts the signaling processes that allow tumors to grow and spread. This cutting-edge approach aims to overcome the limitations of traditional monoclonal antibodies and offers promising new avenues for tackling cancer’s incessant complexity. The company's business model is built upon a robust pipeline strategy, where promising drug candidates are both developed in-house and guided through strategic collaborations with larger pharmaceutical entities. These collaborations often involve licensing agreements that provide Merus NV with milestone payments and royalties, creating a significant revenue stream. As these partnerships amplify its reach and bolster its financial health, Merus maintains a primary focus on advancing its leading drug candidates through clinical trials. By aligning groundbreaking science with strategic collaborations, Merus NV works to convert its innovations into viable products that can potentially transform the landscape of cancer treatment, striving to turn scientific potential into practical solutions and profitable outcomes.

MRUS Intrinsic Value
24.64 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Merus NV's Total Equity?
Total Equity
703.3m USD

Based on the financial report for Sep 30, 2024, Merus NV's Total Equity amounts to 703.3m USD.

What is Merus NV's Total Equity growth rate?
Total Equity CAGR 5Y
56%

Over the last year, the Total Equity growth was 79%. The average annual Total Equity growth rates for Merus NV have been 51% over the past three years , 56% over the past five years .

Back to Top